Submission of Annual Secretarial Compliance Report for the period ended 31st March, 2026

Mangalam Drugs & Organics Limited has filed its annual secretarial compliance report for FY2025-26 with multiple regulatory deviations. The company failed to maintain the required board composition — at least half of directors as Independent Directors — from January 16, 2026 to March 31, 2026 after one Independent Director resigned. The Audit Committee and Nomination & Remuneration Committee (NRC) also fell below the required minimum composition during January 16 to February 6, 2026, though new Independent Directors were appointed from February 6, 2026. Additionally, the company missed the 45-day deadline for submitting Q2 FY2025 quarterly and year-to-date financial results, and delayed disclosure of the board meeting outcome held on January 15, 2026 beyond the required 30-minute window. Critically, the report also highlights loan defaults: Bank of Maharashtra (₹1979.21 lakh) and Bank of Baroda (₹606.08 lakh), both overdue since October 2025. Various dispute cases with suppliers and lenders are also under adjudication. The company has no material subsidiaries and no prior-year observations to address.